Martina Anna Finetti
Total Page:16
File Type:pdf, Size:1020Kb
Next-Generation Sequencing Identifies Mechanisms Of Tumourigenesis Caused By Loss Of SMARCB1 In Malignant Rhabdoid Tumours Martina Anna Finetti Thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy Newcastle University Faculty of Medical Sciences Northern Institute for Cancer Research December 2014 Declaration I certify that no part of the material documented in this thesis has previously been submitted for a degree or other qualification in this or any other university. I declare that this thesis represents my own unaided work, carried out by myself, except where it is acknowledged otherwise in the thesis text. Martina Finetti December 2014 I Acknowledgements I would like to express my sincere gratitude to my supervisors, Dr. Daniel Williamson, Professor Steven Clifford, and Professor Simon Bailey. Their continuous support and their extraordinary knowledge of paediatric cancer and bioinformatics have helped me immensely throughout my research. I would also like to thank my assessors Professor John Lunec and Dr. Luke Gaughan and Professor Craig Robson for their constant guidance and encouragement for the last four years. I would like to thank the members of the Paediatric Brain Tumour Research Group. In particular I would like to thank Dr. Rebecca Hill, Matthew Selby and Dr Dolores Hamilton for the support, the encouragement and the time spent together in good and bad times. Special thanks go to all people at Sir James Spence Institute for their technical help and support. I would in particular thank Stefano and Alicia for our friendship: thank you for the moral support and the all the laughs we shared in between experiments! I would like to thank the NECCR, Children with cancer UK, Brain Trust, Love Oliver, CCLG, Karen and Iain Wark, The Smiley Ridley Fund, whose financial support made this project possible. Finally, I would like to thank my family: my Mum Chiara, Lorenzo, Giulia and Al. Thank you for supporting me especially in the bad times and for all your caring: without your encouragement I would not have made it. My final thanks are reserved for my Dad Roberto: your love for knowledge inspires me to continue my studies and accomplish my dreams. II Dedication This thesis is dedicated to the memory of my Dad, Roberto Finetti. How I wish, how I wish you were here. We're just two lost souls swimming in a fish bowl, year after year, Running over the same old ground. What have we found? The same old fears. Wish you were here -Pink Floyd- III Abstract Introduction: Malignant Rhabdoid Tumours (MRT) are unique malignancies caused by biallelic inactivation of a single gene (SMARCB1). SMARCB1 encodes for a protein that is part of the SWI/SNF chromatin remodelling complex, responsible for the regulation of hundreds of downstream genes/pathways. Despite the simple biology of these tumours, no studies have identified the critical pathways involved in tumourigenesis. The understanding of downstream effects is essential to identifying therapeutic targets that can improve the outcome of MRT patients. Methods: RNA-seq and 450K-methylation analyses have been performed in MRT human primary malignancies (n > 39) and in 4 MRT cell lines in which lentivirus was used to re-express SMARCB1 (G401, A204, CHLA-266, and STA-WT1). The MRT cell lines were treated with 5-aza-2 -deoxycytidine followed by global gene transcription analysis (RNA-seq and 450K-methylation) to investigate how changes in methylation lead to tumourigenesis. Results: We show that primary Malignant Rhabdoid Tumours present a unique and distinct expression/methylation profile which confirms that MRT broadly constitute a single and different tumour type from other paediatric malignancies. However, despite their common cause MRT can be can sub-group by location (i.e. CNS or kidney). We observe that re-expression of SMARCB1 in MRT cell lines determines activation/inactivation of specific downstream pathways such as IL-6/TGF beta. We also observe a direct correlation between alterations in methylation and gene expression in CD44, GLI2, GLI3, CDKN1A, CDKN2A and JARID after SMARB1 re-expression. Loss of SMARCB1 also promotes expression of aberrant isoforms and novel transcripts and causes genome-wide changes in SWI/SNF binding. Conclusion: Next generation transcriptome and methylome analysis in primary MRT and in functional models give us detailed downstream effects of SMARCB1 loss in Malignant Rhabdoid Tumours. The integration of data from both primary and functional models has provided, for the first time, a genome-wide catalogue of SMARCB1 tumourigenic changes (validated using systems biology). Here we show how a single IV deletion of SMARCB1 is responsible for deregulation of expression, methylation status and binding at the promoter regions of potent tumour-suppressor genes. The genes, pathways and biological mechanisms indicated as key in tumour development may ultimately be targetable therapeutically and will lead to better treatments for what is currently one of the most lethal paediatric cancers. V List of abbreviation H2A Histone 2A µg Microgram µl Microliter 3’ UTR Three Prime Untranslated Region 5-azaCdR 5-Aza-2’-Deoxycytidine A Adenine AATK Apoptosis-Associated Tyrosine Kinase Ab Antibody ABR Active BCR-Related AKT V-Akt Murine Thymoma Viral Oncogene AML Acute Myelogenous Leukaemia APC Adenomatous Polyposis Coli ARID1A/ BAF250a AT Rich Interactive Domain 1A (SWI-Like) VI ATPase Adenylpyrophosphatase ATRT Atypical Teratoid Rhabdoid Tumours AZA 5-Aza-2-Deoxycytidine B2M Beta-2-Microglobulin BAF155 BRG1-Associated Factor 155 BAF170 BRG1-Associated Factor 170 BASH Beadarray Subversion Of Harshlight BCA Bicinchoninic Acid Assay BCL2 B-Cell CLL / Lymphoma 2 B-FABP Brain Fatty Acid-Binding Protein BHLHE40 Basic Helix-Loop-Helix Family, Member E40 BID BH3 Domain-Containing Proapoptotic Bcl2 Family Member BK PDZ-Binding Kinase BLAST Basic Local Alignment Search Tool VII BM1 Polycomb Complex Protein BMI1 BMI Polycomb Ring Finger Oncogene BP Base Pair BRAF V-Raf Murine Sarcoma Viral Oncogene Homologue B1 BRCA1/2 Breast Cancer 1/2 BRG1 Brahma-Related Gene 1 BRM Brahma BTG4 B-Cell Translocation Gene 4 C Cytosines C2 Curated Gene Sets C6 Oncogenic Signatures CASP8 Caspase 8, Apoptosis-Related Cysteine Peptidase CCDC46 Coiled-Coil Domain Containing 46 CCDC74B Coiled-Coil Domain Containing 74B CCLG Children's Cancer And Leukaemia Group VIII CCNB1 Cyclin B1 CD8 (Cluster Of Differentiation 8 CDH1 Cadherin 1, Type 1, E-Cadherin (Epithelial) CDKN1A Cyclin Dependent Kinase Inhibitor 1A CDKN2A Cyclin-Dependent Kinase Inhibitor 2A cDNA Complementary DNA CDS Similarly Coding Sequences CHD5 Chromo domain Helicase DNA Binding Protein 5 ChIP Chromatin Immunoprecipitation ChIP-seq Chromatin Immunoprecipitation Sequencing CLAS Classic Type Medulloblastoma CML Chronic Myelogenous Leukaemia CNAs Copy-Number Aberrations CNN Copy Number Neutral CNS Central Nervous System IX COL1A2 Collagen, Type I, Alpha 2 Conc Concentration CpG Cytosine-Guanine Dinucleotide cRNA Complementary RNA CTCF CCCTC-Binding Factor (Zinc Finger Protein) CTL Control CTTNB1 Catenin (Cadherin-Associated Protein), Beta 1 Cy3 Cyanine 3 Dye Cy5 Cyanine 5 Dye DAVID Discovery Database For Annotation, Visualization And Integrated DAZ Deleted In Azoospermia DCLK1 Doublecortin-Like Kinase 1 DHH Desert Hedgehog DLC1 Deleted In Liver Cancer 1 DMSO Dimethyl Sulfoxide X DN Dominant Negative DN Desmoplastic / Nodular Medulloblastoma DNA Deoxyribose Nucleic Acid DNA2 DNA Replication Helicase/Nuclease 2 DNM3OS NM3 Opposite Strand/Antisense RNA DNMT1 DNA Methyltransferase 1 DNMT3A DNA Methyltransferase 3A DNMT3B DNA Methyltransferase 3B dNTPs Nucleoside Triphosphates Containing Deoxyribose DRAXIN Dorsal Inhibitory Axon Guidance Protein E. coli Escherichia Coli E2F1 E2F Transcription Factor 1 E2F3 E2F Transcription Factor 3 E2F4 E2F Transcription Factor 4 ECRT Extra Cranial Rhabdoid Tumours XI EGFR Epidermal Growth Factor Receptor EGL External Granule Layer EPCAM Epithelial Cell Adhesion Molecule ER- Estrogen-Receptor Negative ERBB2 V-Erb-B2 Erythroblastic Leukaemia Viral Oncogene Homologue2,Neuroma / Glioblastoma ES Embryonic Stem ES Enrichment Score EU-RHAB European Rhabdoid Registry EWAS Epigenome-Wide Association Studies EWS Ewing Sarcoma Breakpoint Region 1 EZH2 Enhancer Of Zeste Homolog 2 FBXW8 F-Box And WD Repeat Domain Containing 8, FDR False Discovery Rate FPKM Fragments Per Kilo-Base Of Exon Per Million Fragments Mapped) XII FPKM Fragments Per Kilobases Per Millon Reads Fwd Forward G Guanine GA Genome Analyser Gal-1 Galactokinasi 1 GALNT2 Polypeptide N-Acetylgalactosaminyltransferase 2 GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase GC% Guanine-Cytosine Content GCS Genome Analyser Control Software gDNA Genomic DNA GEO Gene Expression Omnibus GFAP Glial Fibrillary Acidic Protein GLI1 GLI Family Zinc Finger 1 GLI2 GLI Family Zinc Finger 2 GLI2 GLI Family Zinc Finger 2 XIII GLI3 GLI Family Zinc Finger 3 GLI3 GLI Family Zinc Finger 3 GPx-1 Glutathione Peroxidase 1 GPx-2 Glutathione Peroxidase 2 GSEA Gene Set Enrichment Analysis GTP Guanine Triphosphate Gy Gray (Unit) g G-Force H2.AZ Variant Histone 2 Az H2B Histone 2B H2O Dihydrogen Monoxide H3 Histone 3 H3K27me3 Histone 3 Lysine 27 Trimethylation H3K36me3 Histone 3 Lysine 36 Trimethylation H3K4me3 Histone 3 Lysine 4 Trimethylation XIV H4 Histone 4 HATs Histone Acetyltransferases HC Hierarchical Clustering HC Hierarchical Clustering HDAC1 Histone Deacetylase 1 HDAC2 Histone Deacetylase 2 HDACs Histone Deacetylase HDCT High-Dose-Chemotherapy